New antibody shot aims to tame HIV in early trial
NCT ID NCT07392372
First seen Feb 06, 2026 · Last updated May 16, 2026 · Updated 14 times
Summary
This early-stage study tests a lab-made antibody called BNT351 in up to 61 adults, both with and without HIV. The main goals are to check safety, how long the antibody stays in the body, and whether it can lower HIV levels in people with the virus. This is not a cure—participants may still need ongoing HIV medication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV -1 INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CRS Mannheim
RECRUITINGMannheim, 68167, Germany
-
Johns Hopkins
RECRUITINGBaltimore, Maryland, 21205-1832, United States
-
UK Köln
NOT_YET_RECRUITINGCologne, 50937, Germany
Conditions
Explore the condition pages connected to this study.